These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 104308)

  • 1. Radiation therapy in carcinoma of prostate: past achievements and future progress.
    Hazra TA
    Prog Clin Biol Res; 1978; 25():99-104. PubMed ID: 104308
    [No Abstract]   [Full Text] [Related]  

  • 2. Late morbidity and oncological outcome after radical hypofractionated radiotherapy in men with prostate cancer.
    Di Staso M; Bonfili P; Gravina GL; Di Genesio Pagliuca M; Franzese P; Buonopane S; Osti MF; Valeriani M; Festuccia C; Enrici RM; Tombolini V
    BJU Int; 2010 Nov; 106(10):1458-62. PubMed ID: 20518760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute side effects during 3-D-planned conformal radiotherapy of prostate cancer. Differences between patient's self-reported questionnaire and the corresponding doctor's report.
    Goldner G; Wachter-Gerstner N; Wachter S; Dieckmann K; Janda M; Pötter R
    Strahlenther Onkol; 2003 May; 179(5):320-7. PubMed ID: 12740659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy.
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):397-405. PubMed ID: 15890581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer.
    Aillères N; Azria D; Thézenas S; Barbier N; Fenoglietto P; Delard R; Hay MH; Dubois JB
    Cancer Radiother; 2004 Apr; 8(2):59-69. PubMed ID: 15063872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
    Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization.
    Woel R; Beard C; Chen MH; Hurwitz M; Loffredo M; McMahon E; Ching J; Lopes L; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):392-6. PubMed ID: 15890580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity.
    Karlsdóttir A; Muren LP; Wentzel-Larsen T; Dahl O
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1478-86. PubMed ID: 18060703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: a prospective assessment of acute and late treatment toxicity.
    Wahlgren T; Nilsson S; Ryberg M; Lennernäs B; Brandberg Y
    Acta Oncol; 2005; 44(6):633-43. PubMed ID: 16165923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer.
    Fonteyne V; Villeirs G; Lumen N; De Meerleer G
    Radiother Oncol; 2009 Jul; 92(1):42-7. PubMed ID: 19356817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019.
    Lee WR; DeSilvio M; Lawton C; Gillin M; Morton G; Firat S; Baikadi M; Kuettel M; Greven K; Sandler H
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):804-9. PubMed ID: 16289906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields.
    Jani AB; Su A; Correa D; Gratzle J
    Prostate Cancer Prostatic Dis; 2007; 10(1):82-6. PubMed ID: 16983394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
    Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
    Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complications following radiotherapy in gynaecological carcinoma. Comparison between X-ray and megavoltage therapy.
    Punnonen R; Grönroos M; Rauramo L; Voutilainen A; Aho AJ; Hartikainen P
    Ann Chir Gynaecol; 1976; 65(1):62-7. PubMed ID: 829842
    [No Abstract]   [Full Text] [Related]  

  • 16. Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer.
    Jani AB; Parikh SD; Vijayakumar S; Gratzle J
    Urology; 2005 Jun; 65(6):1157-62. PubMed ID: 15913725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer.
    Jani AB; Gratzle J; Myers M
    Prostate Cancer Prostatic Dis; 2005; 8(3):224-8. PubMed ID: 15983626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer.
    Izard MA; Haddad RL; Fogarty GB; Rinks A; Dobbins T; Katelaris P
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):38-47. PubMed ID: 16904516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.